Claris Lifesciences has reportedly received 18 observations from US Food and Drug Administration (USFDA) for its Ahmedabad plant. This was inspected between July 27 and August 4, 2017. The Ahmedabad site is an Ex-Claris injectable site as the company sold its injectable business to Baxter for $625 million.
Claris Lifesciences is engaged in manufacturing of drugs and pharmaceutical products. The Company manufactures and markets products across multiple delivery systems, markets and therapeutic segments, including anesthesia and analgesics, blood products, anti-invective's, critical care, and nephrology.
